Role of CYP2A5 in the bioactivation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 341, Issue 1, 2012, Pages 233-241

  Zhou, Xin ^a   D'Agostino, Jaime ^a   Xie, Fang ^a   Ding, Xinxin ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; 6 O METHYLGUANINE; CYTOCHROME P450 2A5; METHOXSALEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CARCINOGEN DNA INTERACTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME METABOLISM; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; TISSUE LEVEL; WILD TYPE;

ADENOCARCINOMA; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; FEMALE; LUNG; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; NITROSAMINES; PYRIDINES; TISSUE DISTRIBUTION;

EID: 84863341976     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.190173     Document Type: Article

References (40)

1. Ahrendt SA, Decker PA, Alawi EA, Zhu YR, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, and Sidransky D (2001) Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525-1530. (Pubitemid 32947838)
2. Apseloff G, Hilliard JB, Gerber N, and Mays DC (1991) Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice. Xenobiotica 21: 1461-1471.
3. Castonguay A, Stoner GD, Schut HA, and Hecht SS (1983) Metabolism of tobacco-specific N-nitrosamines by cultured human tissues. Proc Natl Acad Sci U S A 80:6694-6697. (Pubitemid 14240161)
4. D'Agostino J, Zhang X, Wu H, Ling G, Wang S, Zhang QY, Liu F, and Ding x (2008) Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers. Drug Metab Dispos 36:2316-2323.
5. Devereux TR, Belinsky SA, Maronpot RR, White CM, Hegi ME, Patel AC, Foley JF, Greenwell A, and Anderson MW (1993) Comparison of pulmonary O6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol Carcinog 8:177-185.
6. Ding X and Coon MJ (1990) Immunochemical characterization of multiple forms of cytochrome P-450 in rabbit nasal microsomes and evidence for tissue-specific expression of P-450s NMa and NMb. Mol Pharmacol 37:489-496. (Pubitemid 20130791)
7. Felicia ND, Rekha GK, and Murphy SE (2000) Characterization of cytochrome P450 2A4 and 2A5-catalyzed 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism. Arch Biochem Biophys 384:418-424. (Pubitemid 32012820)
8. Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific Nnitrosamines. Chem Res Toxicol 11:559-603.
9. Hecht SS, Morse MA, Amin S, Stoner GD, Jordan KG, Choi CI, and Chung FL (1989) Rapid single-dose model for lung tumor induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis 10:1901-1904. (Pubitemid 19244867)
10. Hollander MC, Zhou X, Maier CR, Patterson AD, Ding X, and Dennis PA (2011) A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. Carcinogenesis 32:1279-1284.
11. International Agency for Research on Cancer (2007) IARC Monograph on the Evaluation of Carcinogenic Risks to Humans: Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamine. International Agency for Research on Cancer, Lyon, France.
12. Jalas JR, Ding X, and Murphy SE (2003) Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13. Drug Metab Dispos 31:1199-1202. (Pubitemid 37152969)
13. Jalas JR, Hecht SS, and Murphy SE (2005) Cytochrome P450 enzymes as catalysts of metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco specific carcinogen. Chem Res Toxicol 18:95-110. (Pubitemid 40267791)
14. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415. (Pubitemid 28010927)
15. Labbe G, Descatoire V, Letteron P, Degott C, Tinel M, Larrey D, Carrion-Pavlov Y, Geneve J, Amouyal G, and Pessayre D (1987) The drug methoxsalen, a suicide substrate for cytochrome P-450, decreases the metabolic activation, and prevents the hepatotoxicity, of carbon tetrachloride in mice. Biochem Pharmacol 36:907-914. (Pubitemid 17038038)
16. Li L, Wei Y, Van Winkle L, Zhang QY, Zhou X, Hu J, Xie F, Kluetzman K, and Ding X (2011) Generation and characterization of a Cyp2f2-null mouse and studies on the role of CYP2F2 in naphthalene-induced toxicity in the lung and nasal olfactory mucosa. J Pharmacol Exp Ther 339:62-71.
17. Miyazaki M, Yamazaki H, Takeuchi H, Saoo K, Yokohira M, Masumura K, Nohmi T, Funae Y, Imaida K, and Kamataki T (2005) Mechanisms of chemopreventive effects of 8-methoxypsoralen against 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone-induced mouse lung adenomas. Carcinogenesis 26:1947-1955. (Pubitemid 41631269)
18. Nunes MG, Desai D, Koehl W, Spratt TE, Guengerich FP, and Amin S (1998) Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in human hepatic microsomes by ipomeanol analogs-an exploratory study. Cancer Lett 129:131-138. (Pubitemid 28386593)
19. Peterson LA and Hecht SS (1991) O6-methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis in A/J mouse lung. Cancer Res 51:5557-5564.
20. Peterson LA, Liu XK, and Hecht SS (1993) Pyridyloxobutyl DNA adducts inhibit the repair of O6-methylguanine. Cancer Res 53:2780-2785. (Pubitemid 23180515)
21. Peterson LA, Mathew R, and Hecht SS (1991) Quantitation of microsomal α-hydroxylation of the tobacco-specific nitrosamine, 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanone. Cancer Res 51:5495-5500.
22. Ronai ZA, Gradia S, Peterson LA, and Hecht SS (1993) G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents. Carcinogenesis 14:2419-2422.
23. Schlicht KE, Michno N, Smith BD, Scott EE, and Murphy SE (2007) Functional characterization of CYP2A13 polymorphisms. Xenobiotica 37:1439-1449. (Pubitemid 350146692)
24. Smith TJ, Guo Z, Li C, Ning SM, Thomas PE, and Yang CS (1993) Mechanisms of inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation in mouse by dietary phenethyl isothiocyanate. Cancer Res 53:3276-3282. (Pubitemid 23223297)
25. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, and Ding X (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60:5074-5079.
26. Su T, Sheng JJ, Lipinskas TW, and Ding X (1996) Expression of CYP2A genes in rodent and human nasal mucosa. Drug Metab Dispos 24:884-890. (Pubitemid 26274747)
27. Takeuchi H, Saoo K, Yokohira M, Ikeda M, Maeta H, Miyazaki M, Yamazaki H, Kamataki T, and Imaida K (2003) Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Cancer Res 63:7581-7583. (Pubitemid 37466676)
28. Visoni S, Meireles N, Monteiro L, Rossini A, and Pinto LF (2008) Different modes of inhibition of mouse Cyp2a5 and rat CYP2A3 by the food-derived 8-methoxypsoralen. Food Chem Toxicol 46:1190-1195.
29. von Weymarn LB, Zhang QY, Ding X, and Hollenberg PF (2005) Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis 26:621-629. (Pubitemid 41214152)
30. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, and Lin D (2003) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63:8057-8061. (Pubitemid 37466745)
31. Weng Y, Fang C, Turesky RJ, Behr M, Kaminsky LS, and Ding X (2007) Determination of the role of target tissue metabolism in lung carcinogenesis using conditional cytochrome P450 reductase-null mice. Cancer Res 67:7825-7832. (Pubitemid 47281377)
32. Westra WH, Slebos RJ, Offerhaus GJ, Goodman SN, Evers SG, Kensler TW, Askin FB, Rodenhuis S, and Hruban RH (1993) K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72:432-438. (Pubitemid 23193449)
33. Xie F, Zhou X, Behr M, Fang C, Horii Y, Gu J, Kannan K, and Ding X (2010) Mechanisms of olfactory toxicity of the herbicide 2,6-dichlorobenzonitrile: essential roles of CYP2A5 and target-tissue metabolic activation. Toxicol Appl Pharmacol 249:101-106.
34. Xie F, Zhou X, Genter MB, Behr M, Gu J, and Ding X (2011) The tissue-specific toxicity of methimazole in the mouse olfactory mucosa is partly mediated through target-tissue metabolic activation by CYP2A5. Drug Metab Dispos 39:947-951.
35. Yao M, Ma L, Humphreys WG, and Zhu M (2008) Rapid screening and characterization of drug metabolites using a multiple ion monitoring-dependent MS/MS acquisition method on a hybrid triple quadrupole-linear ion trap mass spectrometer. J Mass Spectrom 43:1364-1375.
36. Zhang X, D'Agostino J, Wu H, Zhang QY, von Weymarn L, Murphy SE, and Ding X (2007) CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone. J Pharmacol Exp Ther 323:570-578. (Pubitemid 350005129)
37. Zhang X, Su T, Zhang QY, Gu J, Caggana M, Li H, and Ding X (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302:416-423. (Pubitemid 34787203)
38. Zhou X, Wei Y, Xie F, Laukaitis CM, Karn RC, Kluetzman K, Gu J, Zhang QY, Roberts DW, and Ding X (2011) A novel defensive mechanism against acetaminophen toxicity in the mouse lateral nasal gland: role of CYP2A5-mediated regulation of testosterone homeostasis and salivary androgen-binding protein expression. Mol Pharmacol 79:710-723.
39. Zhou X, Zhuo X, Xie F, Kluetzman K, Shu YZ, Humphreys WG, and Ding X (2010) Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model. J Pharmacol Exp Ther 332:578-587.
40. Zhu LR, Thomas PE, Lu G, Reuhl KR, Yang GY, Wang LD, Wang SL, Yang CS, He XY, and Hong JY (2006) CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos 34:1672-1676. (Pubitemid 44427469)